EGFR and non-small cell lung carcinoma: For example, in patients with NSCLC, while the response rate of platinum-based doublet is less than 30% [100], a response rate of 80% is observed in patients with an epidermal growth factor receptor (EGFR) driver mutation treated with erlotinib [101].